Jim Barnes
“The moment a patient truly understands their treatment is the moment adherence begins. My job is to make that moment possible, every time, for every article I write.”
Clinical Voice. Patient-Centered Writing.
Jim Barnes is a Doctor of Pharmacy and clinical pharmacy specialist with 18 years of experience bridging the gap between dense pharmaceutical evidence and the patients who need to understand it. His career began on the wards of Vancouver General Hospital, where he developed a deep conviction that accessible, accurate drug information is a patient safety issue — not just a communications challenge.
After a decade in clinical hospital pharmacy, Jim transitioned to medical writing, bringing with him a practitioner’s command of pharmacokinetics, drug-drug interactions, and evidence-based therapeutics. He has since become one of North America’s most sought-after freelance medical writers for content covering Hepatitis C direct-acting antivirals (DAAs), GLP-1 receptor agonists, and obesity pharmacotherapy.
His written work has appeared in leading clinical journals including Hepatology, Obesity Reviews, Clinical Pharmacology & Therapeutics, and Pharmacotherapy. He has contributed to continuing medical education (CME) programs in Canada, the United States, the United Kingdom, and Australia, and his plain-language patient guides on Hepatitis C treatment have been cited by community health organizations across Sub-Saharan Africa.
The moment a patient truly understands their treatment is the moment adherence begins. My job is to make that moment possible, every time, for every article I write.
Published Work & Journal Contributions
A selection of published and contributed works across peer-reviewed journals and clinical education platforms.
- Pangenotypic Regimens for Hepatitis C: A Pharmacist’s Guide to Patient Counseling on Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir
- GLP-1 Receptor Agonists in Obesity Management: Clinical Efficacy, Mechanisms, and Patient Selection Criteria
- Drug Interaction Profiles of Direct-Acting Antivirals: A Practical Reference for Community Pharmacists
- Semaglutide vs Liraglutide in Clinical Practice: What Patients Need to Know About Dosing, Side Effects, and Expectations
- SVR12 as a Communication Tool: How to Explain Hepatitis C Cure Rates to Patients Without Overpromising
- Obesity Stigma in Healthcare Settings: Language Recommendations for Medical Writers and Patient Educators
- Real-World HCV Treatment Completion Rates with Generic DAAs in Low-Income Settings: Patient Education as an Adherence Driver
- Pharmacoeconomics of Generic Hepatitis C Treatment: A Plain Language Evidence Review for Patient Advocacy Organizations
- Weight Loss Pharmacotherapy After Bariatric Surgery: A Clinical and Communication Review
Editorial Standards & Conflict of Interest
All content authored by Jim Barnes for Sunny Pharma® is developed independently, with no direction from pharmaceutical manufacturers or commercial partners. Jim’s compensation is a fixed editorial fee unrelated to commercial outcomes. He holds no equity, advisory roles, or speaking relationships with any Hepatitis C or weight management pharmaceutical company. All clinical claims are sourced directly from FDA-approved prescribing information, AASLD/IDSA HCV guidelines, or peer-reviewed literature.
Last credentials verified: January 2025 | Content reviewed by: Wendy Chamberlain, Editor-in-Chief